Hydroxy naphthoquinone derivatives, their preparations for treating and preventing theileriosis in cattle and sheep, processes for their synthesis; naphthoquinone derivatives

Claim 2

A compound of formula (II) a tautomer or a pharmaceutically acceptable salt thereof wherein R 2 an unsubstituted monocyclic cycloalkyl group having 7 to 12 carbon atoms.

Claim 3

A compound as claimed in claim 1 wherein R 2 has 7 or 8 carbon atoms.

Claim 4

A compound as claimed in claim 1 or claim 2 in the form of a sodium, potassium or N-methyl glucamine salt.

Claim 5

2-Cycloheptyl-3-hydroxy-1, 4-naphthoquinone.

Claim 6

2-Cycloheptyl-3-hydroxy-1, 4-naphthoquinone.

Claim 7

2-Cyclooctyl-3-hydroxy-1, 4-naphthoquinone.

Claim 8

2-Cyclooctyl-3-hydroxy-1, 4-naphthoquinone.

Claim 9

A compound of formula (II) as defined in any one of claims 1 to 5 for use in veterinary medicine.

Claim 10

A process for producing a compound of formula (II) as defined in claim 1, characterised in that the corresponding 3-halogeno analogue of the compound is hydrolysed under alkaline conditions to provide the 3-hydroxy-2-substituted compound.

Claim 11

A process for producing a compound of formula (11), as defined in claim 1, characterised in that a compound of formula (IV) wherein R 4 is a halogeno, hydroxy, acetoxy or alkoxy group is reacted with a cycloalkyl donor compound corresponding with the desired cycloalkyl group R 2 , and when R 4 is other than hydroxy, hydrolysing the resultant 3-halogeno- or 3-acetoxy- or 3-alkoxy- compound under alkaline conditions.

Claim 12

A process for producing a compound of formula (II), as defined in claim 1, characterised in that the next higher Regier homologue, 2-cycloalkyl-methyl-3-hydroxy-1, 4-naphthoquinone, is subjected to Hooker oxidation.

Claim 13

A composition for treating theileriosis in appropriate mammals characterised in that a compound as claimed in any one of claims 1 to 5 is presented in association with a pharmaceutically acceptable carrier.